- PR Newswire•6 days ago
SUNNYVALE, Calif., Feb. 21, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), announced today that the Company will present at Cowen and Company's 37 th Annual Healthcare Conference in Boston on ...
- PR Newswire•11 days ago
SUNNYVALE, Calif., Feb. 16, 2017 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today data from a prospective, Phase II, 17-center study which showed that treatment with the CyberKnife® System for low- and intermediate-risk prostate cancer provides excellent long-term results. At five years, the disease-free survival rate for low-risk prostate cancer patients was 100 percent and for intermediate-risk patients was 88.5 percent. A low prostate specific antigen (PSA) value is associated with a reduced risk of cancer recurrence or metastases. According to the study, the five-year median PSA was 0.1 ng/mL for low- and intermediate-risk prostate cancer patients receiving stereotactic body radiation therapy (SBRT) administered with the CyberKnife System.
- Motley Fool•14 days ago
Making surgical robots is an exciting business, but only one is investment-worthy right now.
ARAY : Summary for Accuray Incorporated - Yahoo Finance
Accuray Incorporated (ARAY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||4.95 x 100|
|Ask||5.70 x 100|
|Day's Range||5.35 - 5.45|
|52 Week Range||4.45 - 6.39|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-17.08|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|